Imogen was part of the team until 2024, leaving the team after completing her PhD in the biomarkers lab at the UK Dementia Research Institute. She has a BSc in Biochemistry from the University of Exeter and an MSc in Molecular Neuroscience from the University of Bristol. She joined the team in 2018 as a research assistant, helping to co-ordinate the biomarker samples within GENFI. Since 2021 she has been working on developing biomarkers for progranulin-associated FTD as part of her PhD. In 2021 she was shortlisted for the MRC Max Perutz Science Writing Award for a piece called: ‘It’s in the blood: the race to treat frontotemporal dementia.’, and she is also the UCL 2023 winner of the 3-minute Thesis competition (video of her performance here).
- AAIC FTD-PIA 2023 (Amsterdam, July 2023): Endogenous granulin peptides as novel CSF biomarkers of progranulin-associated FTD
- ADPD 2023 (Gothenburg, March 2023): Novel CSF biomarkers for progranulin-associated frontotemporal dementia
- ISFTD 2022 (Lille, November 2022): Prosaposin: a lysosomal CSF biomarker of progranulin-associated frontotemporal dementia
- Fluid biomarkers in frontotemporal dementia: past, present and future. J Neurol Neurosurg Psychiatry.2021;92(2):204-215.
- Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature. Swift IJ, Bocchetta M, Benotmane H, Woollacott IO, Shafei R, Rohrer JD. Neurobiol Aging. 2021;99:100.e9-100.e15.
- AAIC 2023 (Amsterdam, July 2023): Endogenous granulin peptides as novel CSF biomarkers of progranulin-associated frontotemporal dementia
- Vesicle Trafficking and Pathways to Neurodegeneration 2021 (virtual, May 2021):Differential pattern of lysosomal dysfunction are seen in different clinicopathological forms of primary progressive aphasia
- ARUK 2021 (virtual, March 2021): A systematic review of progranulin concentrations in biofluids in over 7,000 people – assessing the pathogenicity of GRN mutations and other influencing factors
